Podcast


Presenter: G. Michael Allan MD CCFP James McCormack BSc(Pharm) PharmD Paul Fritsch MD CCFP

Podcast: BS Medicine Episode #481: Clearing up the evidence for topical acne combination products
0:00

In episode 481, James and Mike invite Paul Fritsch to go through all the evidence for the benzoyl peroxide/adapalene and benzoyl peroxide/clindamycin combinations that we use for acne. Call us crazy, but we focus on the important outcome of whether or not the patient thinks the treatment worked. We provide all the info and very simple numbers that will help you with shared-decision making for your patients who are trying to figure out which product to use.

 

Tools for Practice

Clearing up the evidence for topical acne combination products




CFPCLearn Logo

Listening to the Podcast can earn you MainPro+ Credits

Join Now

Already a CFPCLearn Member? Log in



Latest Podcasts

In the Clinic Episode 42: Lower Urinary Tract Symptoms

In this episode of In the Clinic, Mike and Jess invite back Dr. Émélie Braschi.  The team discusses Per Colate, a 72-year-old male coming in for lower urinary tract symptoms To earn…
Listen 0.5 credits available

In the Clinic Episode 41: Prenatal Screening for Fetal Anomalies

In this episode of In the Clinic, Mike and Jess invite back Dr. Jennifer Young.  The team discusses Annie Ploidy, a 36-year-old female coming in for prenatal screening. To earn an additional…
Listen 0.5 credits available

FM Rounds #18: Inclusive by Default: From Minority Stress to Trauma-Informed Primary Care

Over 60% of Canadian trans adults rate their mental health as fair-to-poor and are twice as likely to avoid seeking primary care. Avoidance isn’t random – it’s the predictable outcome…
Listen 0.5 credits available

Presenter(s):

G. Michael Allan MD CCFP James McCormack BSc(Pharm) PharmD Paul Fritsch MD CCFP

This content is certified for MainPro+ Credits, log in to access


Presenter(s):

  • G. Michael Allan MD CCFP
  • James McCormack BSc(Pharm) PharmD
  • Paul Fritsch MD CCFP

Spearkers do not have any conflicts of interest to declare.